GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Investments And Advances

Estrella Immunopharma (Estrella Immunopharma) Investments And Advances : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Investments And Advances?

Estrella Immunopharma's Investments And Advances for the quarter that ended in Mar. 2024 was $0.00 Mil.


Estrella Immunopharma Investments And Advances Historical Data

The historical data trend for Estrella Immunopharma's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Investments And Advances Chart

Estrella Immunopharma Annual Data
Trend Jun21
Investments And Advances
-

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Estrella Immunopharma Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Estrella Immunopharma (Estrella Immunopharma) Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines